Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company is headquartered in The Woodlands, Texas.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-17.02M |
| Operating Margin | 0.00% |
| Return on Equity | -238.90% |
| Return on Assets | -122.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $10.85 |
| Price-to-Book | 0.25 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 543,000 |
| Float | 526,440 |
| % Insiders | 4.11% |
| % Institutions | 4.22% |
Volatility is currently contracting
Data demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation
Patent Broadens Intellectual Property Protecting Advanced Autonomic Nervous System Assessment Technologies Designed to Enhance Patient Selection, Treatment Precision and Future Clinical Applications THE WOODLANDS, TX, July 23, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,471,776, titled "ANS Assessment Systems, Kits, and Methods," further strengthening the Company's intellectual property portfolio supporting its proprietary autonomic nervous system technologies.
Newly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans THE WOODLANDS, TX, July 15, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 12,611,134, titled “Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder.
THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on November 19, 2025 (the “November 2025 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding November 2025 Warrants to purchase an aggregate of 428,731 shares of the Company's common stock at the amended and reduced exercise price of $6.00. The resale of the shares of common stock issuable upon exercise of the November 2025 Warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333- 291825). The gross proceeds from the exercise of the warrants are expected to be approximately $2.6 million, prior to deducting financial advisory fees and estimated offering expenses.
Autonomix Medical Inc (NASDAQ:AMIX) has been granted a new patent strengthening its neural sensing intellectual property, the company said, adding to a portfolio it ties to what it called the multi-billion-dollar denervation market. Autonomix said the patent grant covers its neural sensing technology and reinforces its intellectual property position.
IP portfolio reflects Autonomix's neural sensing leadership in multi-billion-dollar denervation market Technical highlights on newly issued patent include real-time nerve monitoring and diagnostic evaluation THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has been granted Canadian Patent No. 3,158,197, titled "Endoscopic Sympathectomy Systems and Methods.
Platform Expected to Target Expansion into Multi-Billion-Dollar Cardiovascular Market with Potential Class II Diagnostic Regulatory Path Architecture Supports Future Expansion into Denervation, including Renal, Pulmonary, Cardiac, Splanchnic and Other Nerve-Targeted Applications, with Potential Compatibility Across Multiple Denervating Technologies THE WOODLANDS, TX, June 22, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the development of a proprietary standalone neural sensing platform following preclinical results showing evidence of the ability to identify renal neural activity and detect real-time changes in neural activity following intervention. The standalone neural sensing platform will be built on the same core sensing technology as Autonomix's lead pancreatic cancer pain program and is being developed in parallel with that initiative, enabling a capital-efficient expansion into cardiology, which represents a significant new therapeutic market opportunity.
THE WOODLANDS, TX, June 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-21 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on June 24, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market on June 24, 2026 on a post-split basis, under the existing ticker symbol “AMIX” but with a new CUSIP number 05330T304.
Access the segment here THE WOODLANDS, TX, June 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest CEO Corner segment featuring President and Chief Executive Officer, Brad Hauser. As part of the segment, Mr.
Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AMIX and any ticker you trade — then tracks every position and per-strategy win rate.
